Roland Diel1, Robert Loddenkemper2, Karen Meywald-Walter3, Rene Gottschalk4, Albert Nienhaus5. 1. School of Public Health, Heinrich Heine University of Düsseldorf, Düsseldorf. Electronic address: Roland.Diel@uni-duesseldorf.de. 2. German Central Committee Against Tuberculosis, Lungenklinik Heckeshorn, HELIOS, Klinikum Emil von Behring, Berlin. 3. Public Health Department Hamburg-Central, Hamburg, Germany. 4. Institute of Medical Virology, University Hospital, Johann Wolfgang Goethe University, Frankfurt am Main. 5. Institution for Statutory Accident Insurance and Prevention in the Health and Welfare Services, Hamburg, Germany.
Abstract
RATIONALE: Mycobacterium tuberculosis (MTB)-specific interferon-gamma release assays (IGRAs) are an alternative or adjunct to the tuberculin skin test (TST) in identifying recent contacts with latent tuberculosis infection (LTBI), but there are scarce data directly comparing performance of the tests. OBJECTIVE: To evaluate the agreement between both IGRAs and to determine which contacts were most likely to represent LTBI, the QuantiFERON-TB-Gold In Tube assay (QFT) and the T-Spot.TB test (T-Spot) were compared in TST-positive persons recently exposed to pulmonary tuberculosis cases. METHODS: Prospectively enrolled close contacts (n = 812) of 123 culture-confirmed tuberculosis source cases underwent IGRA testing using standardized collected data. Factors independently influencing the risk of MTB infection and their interactions with each other were evaluated by multivariate analysis. RESULTS: Five variables were found to significantly predict a positive IGRA test result (age, source case acid-fast bacilli positive and/or coughing, cumulative exposure time, foreign origin). There was excellent agreement between the two IGRAs (93.9%, kappa = 0.85), with QFT finding 30.2% of contacts positive and T-Spot finding 28.7%. Assuming positivity to both IGRAs as true infection, sensitivity of the TST at > 10 mm was 72% and at > 15 mm was 39.7%. The use of either IGRA as a replacement for the TST would decrease the number of LTBI suspects to be investigated by approximately 70%. CONCLUSIONS: IGRAs are a more accurate indicator of the presence of LTBI than the TST. Both QFT and T-Spot appear to be valuable public health tools, showing excellent agreement with each other.
RATIONALE: Mycobacterium tuberculosis (MTB)-specific interferon-gamma release assays (IGRAs) are an alternative or adjunct to the tuberculin skin test (TST) in identifying recent contacts with latent tuberculosis infection (LTBI), but there are scarce data directly comparing performance of the tests. OBJECTIVE: To evaluate the agreement between both IGRAs and to determine which contacts were most likely to represent LTBI, the QuantiFERON-TB-Gold In Tube assay (QFT) and the T-Spot.TB test (T-Spot) were compared in TST-positive persons recently exposed to pulmonary tuberculosis cases. METHODS: Prospectively enrolled close contacts (n = 812) of 123 culture-confirmed tuberculosis source cases underwent IGRA testing using standardized collected data. Factors independently influencing the risk of MTB infection and their interactions with each other were evaluated by multivariate analysis. RESULTS: Five variables were found to significantly predict a positive IGRA test result (age, source case acid-fast bacilli positive and/or coughing, cumulative exposure time, foreign origin). There was excellent agreement between the two IGRAs (93.9%, kappa = 0.85), with QFT finding 30.2% of contacts positive and T-Spot finding 28.7%. Assuming positivity to both IGRAs as true infection, sensitivity of the TST at > 10 mm was 72% and at > 15 mm was 39.7%. The use of either IGRA as a replacement for the TST would decrease the number of LTBI suspects to be investigated by approximately 70%. CONCLUSIONS: IGRAs are a more accurate indicator of the presence of LTBI than the TST. Both QFT and T-Spot appear to be valuable public health tools, showing excellent agreement with each other.
Authors: Ravy K Vajravelu; Mark T Osterman; Faten N Aberra; Jason A Roy; Gary R Lichtenstein; Ronac Mamtani; David S Goldberg; James D Lewis; Frank I Scott Journal: Inflamm Bowel Dis Date: 2017-12-19 Impact factor: 5.325
Authors: Malathesha Ganachari; Jorge A Ruiz-Morales; Juan C Gomez de la Torre Pretell; Jeffrey Dinh; Julio Granados; Pedro O Flores-Villanueva Journal: PLoS One Date: 2010-01-25 Impact factor: 3.240
Authors: Felix C Ringshausen; Stephan Schlösser; Albert Nienhaus; Anja Schablon; Gerhard Schultze-Werninghaus; Gernot Rohde Journal: J Occup Med Toxicol Date: 2009-06-08 Impact factor: 2.646
Authors: Martine G Aabye; Pernille Ravn; George PrayGod; Kidola Jeremiah; Apolinary Mugomela; Maria Jepsen; Daniel Faurholt; Nyagosya Range; Henrik Friis; John Changalucha; Aase B Andersen Journal: PLoS One Date: 2009-01-19 Impact factor: 3.240